Currently, the analyst consensus on Ovintiv is a Strong Buy with an average price target of $53.93, representing a 24.92% upside. In a report released today, Barclays also maintained a Buy rating on ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
RBC Capital analyst Gregory Pardy maintained a Hold rating on Ovintiv (OVV – Research Report) on November 8 and set a price target of ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Price Action: AbbVie stock is down 10.6% at $178.32, while Bristol Myers Squibb stock is up 13% at $61.20 during the ...
Corteva's Q3 results showed weak growth in Latin America, but benefits from raw material cost deflation. Read why I reiterate ...
TipRanks on MSN1d
CoreCivic (CXW) to Benefit Immensely from Trump’s Policy ShiftExpectations that the incoming Trump administration will strengthen the country’s stance on mass migration have thrust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback